Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Botox injections may help stroke survivors move their arms better

NCT ID NCT03783572

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observed 18 chronic stroke patients who received botulinum toxin injections into their elbow muscles as part of routine care. The goal was to see if the injections reduced muscle tightness (spasticity) and improved active arm extension. Researchers measured muscle activity and spasticity before and after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Dec 2020

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Stroke group : Inclusion Criteria: * Cortical and/or subcortical ischemic or haemorrhagic stroke for at least 6 months; * Indication to an injection of BTA in the elbow flexor muscles according to the usual clinical criteria: request of elbow extension improvement with a functional or aesthetic objective; * Being under prescription of abobotulinum toxin A (DYSPORT®, Ipsen-Pharma); * Ability of active elbow extension\> 20 degrees; * Limitation of active movement of elbow extension \> 15 degrees or decreased or 50% decrease in the active elbow extension rate; * Patients who have never been treated with BTX or only a first injection that having targeted the elbow flexors more than 4 months ago; * Age\> 18 years; * Signature of informed consent; * Subject affiliated to the social security coverture. Exclusion Criteria: * Passive limitation of elbow extension \> 30 degrees; * Pain during active movements of elbow flexion/extension; * Cognitive disorder with limited comprehension of three basic instructions (like the test of the 3 papers of the MMS); * Evolutionary or decompensated neurological disease; * Unstabilized epilepsy; * Anticoagulant treatment with a curative dose or hemostasis disorder that contraindicates intramuscular injections; * Claustrophobia or metallic foreign bodies contraindicated for MRI; * General contraindication for botulinum toxin injection: hypersensitivity to the active substance or to one of the excipients, swallowing disorder, chronic respiratory disorders, antecedent of myasthenia or Lambert Eaton syndrome; antecedent of neuromuscular disease; surgery with curarization for less than a month; current treatment with aminoglycoside, aminoquinoline, cyclosporine or anticholinesterase. * Presence of skin infection or inflammation at the injection site. * Legal incapacity. * Pregnant or breastfeeding woman; * Woman with a desire to become pregnant within 18 months. * Non-menopausal woman (a postmenopausal state is defined as no menses for 12 months without an alternative medical cause) who does not use one of the following contraceptive methods considered highly effective : intrauterine device, oestroprogestonic contraception or progestogen hormonal contraception associated with inhibition of ovulation, intrauterine hormone-releasing system, or bilateral tubal occlusion. Control group * inclusion criteria: * Age\> 18 years * Signature of informed consent. * exclusion criteria: * History of orthopedic or neurologic disorders; * Subject expert in a sport intensively requiring the upper limbs (at least departmental competition level); * Legal incapacity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle spasticity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Muscle Spasticity stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Toulouse

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.